Amylx Pharmaceuticals Inc vs YieldMax AMZN Option Income Strategy ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.94 (market cap $2.64B), while YieldMax AMZN Option Income Strategy ETF trades at $11.3. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | AMZY | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $24.19 | $15.75 |
52-Week Low | $7.82 | $9.98 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
AMZY trades at $11.35, down 2.32% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has paid consistent weekly dividends, with recent distributions ranging from $0.06 to $0.14 per share. Key resistance and support levels are clustered around $12 and $11, respectively, indicating a tight trading range.
Outlook is cautious due to concerns over NAV erosion from its synthetic option strategy, as highlighted by Seeking Alpha. While high yields attract income seekers, the strategy may cap upside and amplify downside risk. Investors should weigh the income benefits against potential long-term underperformance relative to Amazon.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →